Viatris said it exercised the Option on January 26, 2024 and entered into the Transaction Agreement with Buyer Parent, Viatris Italia S.r.l., and Ipex AB on January 29, 2024, together with the Buyer Parties.

1. 01

   Viatris said it exercised the Option on January 26, 2024 and entered into the Transaction Agreement with Buyer Parent, Viatris Italia S.r.l., and Ipex AB on January 29, 2024, together with the Buyer Parties.

2. 02

   The company said Cooper Consumer Health SAS made a binding offer that granted Viatris the Option, under which the Buyer Parties could be required to acquire substantially all of the over-the-counter products business and related assets and liabilities.

3. 03

   The company said the consultation procedures with employee representatives required by local laws in France, Italy and the Netherlands were completed before the Option was exercised.

4. 04

   The company said closing of the transaction is subject to conditions including approvals from the European Commission and the French Ministry of Economy and consents relating to key supply, license and service contracts. It said it has already received approvals from the Presidency of the Italian Council of Ministries and the Commission for Protection of Competition of the Republic of Serbia.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.